Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial ; day:17 ; month:3 ; year:2023 ; pages:1
Nature medicine ; (17.3.2023), 1
- Creator
-
Vardeny, Orly
Fang, James C.
Desai, Akshay S.
Jhund, Pardeep S.
Claggett, Brian
Vaduganathan, Muthiah
De Boer, Rudolf
Hernandez, Adrian F.
Lam, Carolyn S. P.
Inzucchi, Silvio E.
Martinez, Felipe A.
Kosiborod, Mikhail N.
DeMets, David
O’Meara, Eileen
Zieroth, Shelley
Comin-Colet, Josep
Drozdz, Jaroslaw
Chiang, Chern-En
Kitakaze, Masafumi
Petersson, Magnus
Lindholm, Daniel
Langkilde, Anna Maria
McMurray, John J. V.
Solomon, Scott D.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-023-02302-x
- URN
-
urn:nbn:de:101:1-2023080821131856121670
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vardeny, Orly
- Fang, James C.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Claggett, Brian
- Vaduganathan, Muthiah
- De Boer, Rudolf
- Hernandez, Adrian F.
- Lam, Carolyn S. P.
- Inzucchi, Silvio E.
- Martinez, Felipe A.
- Kosiborod, Mikhail N.
- DeMets, David
- O’Meara, Eileen
- Zieroth, Shelley
- Comin-Colet, Josep
- Drozdz, Jaroslaw
- Chiang, Chern-En
- Kitakaze, Masafumi
- Petersson, Magnus
- Lindholm, Daniel
- Langkilde, Anna Maria
- McMurray, John J. V.
- Solomon, Scott D.
- SpringerLink (Online service)
Other Objects (12)
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Right ventricular ejection fraction
Myocardial Recovery and Relapse in Heart Failure With Improved Ejection Fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Right ventricular ejection fraction
Myocardial Recovery and Relapse in Heart Failure With Improved Ejection Fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Right ventricular ejection fraction
Myocardial Recovery and Relapse in Heart Failure With Improved Ejection Fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction